Abstracts tagged "axial spondyloarthritis"

Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0906 • ACR Convergence 2021
Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Floris van Gaalen¹ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Bone loss paradoxically coexists with bone formation in radiographic axial spondyloarthritis (r-axSpA). Assessing bone mineral density (BMD) in r-axSpA poses challenges, namely because of…
Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Désirée van der Heijde¹, Atul Deodhar², Walter Maksymowych³, Joachim Sieper⁴, Filip Van den Bosch⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Ostor⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Yuanyuan Duan¹¹, Alvina D. Chu¹¹ and In-Ho Song¹², ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Oregon Health & Science University, Portland, OR, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁹Montpellier University, Montpellier, France, ¹⁰AbbVie, North Chicago, IL, ¹¹AbbVie Inc, North Chicago, ¹²AbbVie Inc., North Chicago, IL
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁵, Danting Zhu⁴, David Sandoval Calderon⁴, Proton Rahman⁶ and Denis Poddubnyy⁷, ¹Self Employed 72nd Street Medical Associates, Scarsdale, NY, ²Oregon Health & Science University, Portland, OR, ³CHU Montpellier Montpellier University, Montpellier, France, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Calgary, AB, Canada, ⁶Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…
Abstract Number: 0052 • ACR Convergence 2021
HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
Tejpal Gill¹, Patrick Stauffer¹, Mark Asquith¹, Ted Laderas¹, Tammy Martin², Sean Davin¹, Claire Ramirez¹, Ingrid Lindquist¹, Justine Nguyen¹, stephen Planck¹, Carley Shaut¹, Sarah Diamond¹, James T. Rosenbaum³ and Lisa Karstens¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, and Molecular Microbiology & Immunology, Oregon Health & Sciences University, Portland, OR, ³Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (AxSpA) is immune-mediated inflammatory arthritis, which affects the sacroiliac and spinal joints, and is associated with gut inflammation. Disease pathogenesis is associated…
Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Uta Kiltz¹, Kirsten Hoeper², Ludwig Hammel³, Sebastian Lieb⁴, Andreas Haehle⁴ and Dirk Meyer-Olson⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, ³Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵m&i Fachklinik Bad Pyrmont, Hannover, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0620 • ACR Convergence 2021
Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
krystel aouad¹, Anne Tournadre², Florian LUCASSON¹, Daniel Wendling³, Anna Molto⁴, Bruno Fautrel⁵ and Laure Gossec⁶, ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ²Rheumatology Department, Université Clermont Auvergne, CHU Clermont-Ferrand, INRAE, UNH UMR 1019, Clermont-Ferrand, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Rheumatology department, Cochin hospital, APHP, Paris, France, ⁵Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁶Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Recent data suggest differences between men and women with axial spondyloarthritis (axSpA), in terms of disease activity, disease progression and treatment response [1-3]. Overall,…
Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Atul Deodhar¹, Ricardo Blanco ², Eva Dokoupilova ³, Marleen van de Sande ⁴, Stephen Hall ⁵, Anna Wiksten ⁶, Brian Porter ⁷, Hanno Richards ⁶, Sibylle Haemmerle ⁶ and Jürgen Braun ⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, ⁴Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, ⁵Monash University, Melbourne, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
Abstract Number: 418 • 2019 ACR/ARP Annual Meeting
Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Xiaofei Liu ¹, Yanyan Wang ², Wenji Chen ¹, Shiyan Mo ³, Xiaojian Ji ⁴ and Feng Huang², ¹Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, Hainan, China (People's Republic), ²Department of Rheumatology, Chinese PLA General Hospital, beijing, China (People's Republic), ³Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, ⁴Department of Rheumatology, Chinese PLA GeneralHospital,, Beijing, Beijing, China (People's Republic)
Background/Purpose: Axial spondyloarthritis (axSpA) usually affects young people and may lead to work disability(WD). We used the "Smart-phone SpondyloArthritis Management System”, an interactive mobile health…
Abstract Number: 591 • 2019 ACR/ARP Annual Meeting
Longitudinal Assessment of MRI of the Sacroiliac Joints in the ASAS Classification Cohort: Evolution of Diagnostic Features and Predictive Utility for Axial Spondyloarthritis
Walter P. Maksymowych¹, Xenofon Baraliakos ², Manouk de Hooge ³, Iris Eshed ⁴, Susanne Juhl Pedersen ⁵, Ulrich Weber ⁶, Joachim Sieper ⁷, Stephanie Wichuk ⁸, Denis Poddubnyy ⁹, Martin Rudwaleit ¹⁰, Désirée van der Heijde ¹¹, Robert B.M. Landewé ¹², Joel Paschke ¹³, Robert Lambert ⁸ and Mikkel Østergaard ¹⁴, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Sheba Medical Center, Tel Aviv, Israel, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁷Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁸University of Alberta, Edmonton, Canada, ⁹Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²Amsterdam University Medical Center, Amsterdam, Netherlands, ¹³CARE Arthritis, Edmonton, Canada, ¹⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Follow up of the ASAS Classification Cohort (CC) indicated a high positive predictive value for the ASAS classification criteria derived from baseline patient and…
Abstract Number: 617 • 2019 ACR/ARP Annual Meeting
Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp ¹, Mikhail Protopopov², Fabian Proft ³, Joachim Sieper ³, Hildrun Haibel ³, Martin Rudwaleit ⁴ and Denis Poddubnyy ⁵, ¹Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁴Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Peripheral involvement (PI), such as arthritis, enthesitis, and dactylitis, is common in patients with axial spondyloarthritis (axSpA); data showing the influence of PI on…
Abstract Number: 1013 • 2019 ACR/ARP Annual Meeting
Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis
Olivier Fogel¹, Maud Fagny ², Elodie Roche ³, Nelly Sigrist ³, Jean-François Deleuze ⁴, Maxime Dougados ⁵, Corinne Miceli-Richard ¹ and Jorg Tost ³, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²CEA-CNRGH-Institut François Jacob- Laboratoire Epigenetique et Envrironnement, Evry, Ile-de-France, France, ³CEA-CNRGH-Institut François Jacob- Laboratoire Epigenetique et Envrironnement, Evry, France, ⁴CEA-CNRGH-Institut François Jacob, Evry, France, ⁵Cochin Hospital, Paris, France
Background/Purpose: TNFα inhibitors are an effective treatment for many inflammatory diseases. However, their mechanism of action is more complicated than just blocking the targeted cytokine.…
Abstract Number: 1510 • 2019 ACR/ARP Annual Meeting
Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Philip Mease ², Proton Rahman ³, Victoria Navarro-Compán ⁴, Vibeke Strand ⁵, Theresa Hunter ⁶, David Sandoval ⁷, Jeffrey Lisse ⁷, Fangyi Zhao ⁷ and Helena Marzo-Ortega ⁸, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Memorial University, Newfoundland, NL, Canada, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is an inflammatory condition affecting sacroiliac joints and axial skeleton, characterized by fatigue, spinal pain, and sleep disturbances that negatively affect…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.